Edition:
United States

Obseva SA (OBSV.OQ)

OBSV.OQ on NASDAQ Stock Exchange Global Select Market

17.60USD
12:32pm EDT
Change (% chg)

$0.33 (+1.91%)
Prev Close
$17.27
Open
$17.10
Day's High
$17.74
Day's Low
$17.10
Volume
16,285
Avg. Vol
33,015
52-wk High
$20.31
52-wk Low
$9.05

Chart for

About

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH)... (more)

Overall

Beta: --
Market Cap(Mil.): $257.50
Shares Outstanding(Mil.): 29.63
Dividend: --
Yield (%): --

Financials

  OBSV.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -1.86 -- --
ROI: -66.09 0.63 14.31
ROE: -68.51 1.68 16.04

BRIEF-Obseva SA Presents Clinical Data From Phase III Implant 2 Trial Of Nolasiban In IVF At ASRM

* PRESENTS CLINICAL DATA FROM PHASE III IMPLANT 2 TRIAL OF NOLASIBAN IN IVF AT AMERICAN SOCIETY OF REPRODUCTIVE MEDICINE (ASRM) ANNUAL MEETING

Oct 09 2018

ObsEva plans Swiss listing; trading debut on July 13

ZURICH ObsEva , a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

Jul 06 2018

UPDATE 1-ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 ObsEva, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

Jul 06 2018

ObsEva plans Swiss listing; trading debut on July 13

ZURICH, July 6 ObsEva, a Switzerland-based drug development company, said on Friday it is keen on a secondary listing on the SIX Swiss Exchange in Zurich, with a trading debut on July 13, as the firm seeks to gain more notice from European investors.

Jul 06 2018

BRIEF-Obseva Reports Q1 Loss Per Share $0.54

* OBSEVA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 16 2018

Earnings vs. Estimates